Abstract:Hyperglycaemia is a characteristic of type 2 diabetes. In hepatocytes, impaired insulin sensitivity leads to increased gluconeogenesis and decreased glycogenesis. MicroRNA (miR)‑338‑3p is associated with tumour necrosis factor (TNF)‑α‑induced suppression of hepatic glycogenesis via regulation of protein phosphatase 4 regulatory subunit 1 (PP4R1). However, the effect of miR‑338‑3p on gluconeogenesis in hepatocytes remains unknown. In a previous study, it was demonstrated that miR‑338‑3p is downregulated in the livers of mice and in mouse HEPA1‑6 hepatocytes following treatment with TNF‑α. In the present study, the effect of miR‑338‑3p on TNF‑α‑induced gluconeogenesis in hepatocytes was investigated. The levels of phosphorylated‑FOXO1/FOXO1, phosphoenolpyruvate carboxykinase (PEPCK), peroxisome proliferator‑activated receptor γ coactivator (PGC‑1α) and glucose‑6‑phosphatase (G6Pase) were measured by western blotting. The mRNA levels of PEPCK, PGC‑1α and G6Pase were determined by quantitative polymerase chain reaction. Pyruvate tolerance testing was used to determine the gluconeogenesis of mouse livers. The results demonstrated that treatment with TNF‑α resulted in increased levels of gluconeogenesis in the livers of mice and decreased miR‑338‑3p expression levels in HEPA1‑6 cells. Overexpression of miR‑338‑3p reversed TNF‑α‑induced glucose production via enhancement of phosphorylated forkhead box O1 levels and downregulation of the expression levels of genes associated with gluconeogenesis, including peroxisome proliferator‑activated receptor γ coactivator‑1α, phosphoenolpyruvate carboxykinase and glucose‑6‑phosphatase. However, inhibition of miR‑338‑3p expression was revealed to enhance gluconeogenesis in the livers of mice and in HEPA1‑6 cells. Furthermore, downregulation of PP4R1 was revealed to attenuate the effect on glucose production following treatment with miR‑338‑3p inhibitors. In conclusion, the results of the present study revealed that miR‑338‑3p may be involved in TNF‑α‑mediated gluconeogenesis via targeting of PP4R1 in hepatocytes.

Nfe2 Induces Mir-423-5p to Promote Gluconeogenesis and Hyperglycemia by Repressing the Hepatic Fam3a-Atp-Akt Pathway

Aberrant Hepatic Microrna Expression in Nonalcoholic Fatty Liver Disease

Mir-149 Controls Non-Alcoholic Fatty Liver by Targeting Fgf-21

FAM3C activates HSF1 to suppress hepatic gluconeogenesis and attenuate hyperglycemia of type 1 diabetic mice

Hepatic Activation of the FAM3C-HSF1-CaM Pathway Attenuates Hyperglycemia of Obese Diabetic Mice

FAM3A activates PI3K p110α/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis.

FAM3 Gene Family: A Promising Therapeutical Target for NAFLD and Type 2 Diabetes.

MicroRNA-185-5p inhibits hepatic gluconeogenesis and reduces fasting blood glucose levels by suppressing G6Pase

Hepatocyte-secreted FAM3D Ameliorates Hepatic Steatosis by Activating FPR1-hnRNP U-GR-SCAD Pathway to Enhance Lipid Oxidation

HNF-4α Regulated Mir-122 Contributes to Development of Gluconeogenesis and Lipid Metabolism Disorders in Type 2 Diabetic Mice and in Palmitate-Treated HepG2 Cells

Mir‑338‑3p Mediates Gluconeogenesis Via Targeting of PP4R1 in Hepatocytes.

MiR-337-3p improves metabolic-associated fatty liver disease through regulation of glycolipid metabolism

Fam3a Enhances Adipogenesis of 3T3-L1 Preadipocytes Via Activation of Atp-P2 Receptor-Akt Signaling Pathway

Upregulation of Mir-181A Impairs Hepatic Glucose and Lipid Homeostasis.

Obesity-induced upregulation of miR-483-5p impairs the function and identity of pancreatic β-cells

Microrna-20a-5p Contributes to Hepatic Glycogen Synthesis Through Targeting P63 to Regulate P53 and Pten Expression

Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b

Silencing of FGF‐21 Expression Promotes Hepatic Gluconeogenesis and Glycogenolysis by Regulation of the STAT3–SOCS3 Signal

Mir-548Ag Promotes DPP4 Expression in Hepatocytes Through Activation of TLR(7/8)/NF-κB Pathway

CREB-upregulated lncRNA MEG3 promotes hepatic gluconeogenesis by regulating miR-302a-3p-CRTC2 axis.

MicroRNA-27a/b Negatively Regulates Hepatic Gluconeogenesis by Targeting FOXO1.